E7766

DRUG2 trials

Sponsors

Eisai Inc.

Conditions

Advanced Solid TumorsLymphomaUrinary Bladder Neoplasms

Phase 1

A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102

WithdrawnNCT04109092

Eisai Inc.Urinary Bladder Neoplasms

Start: 2020-02-13End: 2022-09-29Updated: 2020-12-14

Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101

TerminatedNCT04144140

Eisai Inc.Advanced Solid Tumors, Lymphoma

Start: 2020-02-24End: 2022-07-26Updated: 2024-03-07

Related Papers

Abstract P110: Neandertal introgressions contribute to upper aero-digestive tract tumor patient survival and identify patients who may benefit from STING agonist treatment

Molecular Cancer Therapeutics2021-12-01

Abstract 592: Demonstration of E7766, a novel STING agonist, as a potent immunotherapy in BCG-insensitive non-muscle invasive bladder cancer models via intravesical administration

Cancer Research2020-08-157 citations